NLARx Newsletter Header
NLARx News
November 24, 2009
In This Issue
NLARx News
In the States
Outrage of the Week
Good News
Health Reform
Prices & Access
Fraud & Abuse
Conflicts of Interest
Patents & Generics
Advertising & Marketing
Pharma Watch
PBM Watch
Medicare & Medicaid
Safety & Clinical Trials
Electronic Records
Quick Links
Join Our Mailing List
NLARx News
NLARx to Senate: Bring Down Drug Costs in Health Legislation More
Letter from State Legislators to Senator Reid More
NLARx featured in "Rx Reforms to Address Budget Deficits and Ensure Quality of Medication" More
New! Health Reform and Rx - See Our Website for Updates More
NLARx Panel: Evidence Based Prescribing and Conflicts of Interest More
A New Trade Agreement on Drug Pricing and Reimbursement? More
In the States
ILLINOIS: Legislation Expanding Access to Prescription Drugs Becomes Law More
UTAH: Utah Snags $24 Million in Drug Settlement More
MISSOURI: State and St. Louis County Consider Subsidies, Tax Break for Pfizer More
PENNSYLVANIA: Award in Pfizer Hormone Suit More
IOWA: State to Recoup Pharmaceutical Overcharges More
Outrage of the Week
Former Eshoo, Barton Staffers at Center of Genentech Scandal More
Genentech Puts Words In The Mouths Of Politicians More
Good News
Pharma Watchdog Nominated As An FTC Commissioner More
Pharmaceuticals and Health Reform
Health Care Fight Swells Lobbying More
Pharma Fights House Health Bill More
Drug-Price Outcry Threatens to Derail Reform More
Drug Makers Raise Prices in Face of Health Care Reform More
Drug Firms' Tired Song and Dance on Reform More
PhRMA Statement on Senate Health Care Reform Bill More
White House Healthcare Accord with Drug Industry May Be Going Sour More
White House Deal With Drug Makers May Be Unraveling More
Prices and Access to Health Care
Costs Of Prescription Drugs Spike More
Letter to GAO from House Democrats on Pharmaceutical Price Hikes More
AARP Prescription Drug Report More
Congress Asks GAO To Track Drug Pricing More
Rising Prices of Drugs Lead to Call for Inquiry More
PhRMA Statement on Misleading Reports About Price Growth More
PhRMA Statement on Prescription Medicine Cost Growth More
PhRMA Statement on AARP Prescription Drug Report More
Prices for H1N1 Drug Tamiflu Vary Widely for Same Dose More
Fraud and Abuse
Justice Department Warns Drug Companies on Corruption More
Health Fraud Caseload Grows at Justice Department More
Justice Department To Focus On Pharma Fraud Overseas More
Conflicts of Interest
100 Researchers Ask National Institutes of Health To Fund Ethics Research More
Few Universities File Conflict Of Interest Reports More
In Medical Research, Who Should Define Conflict of Interest? More
Grassley Presses Medical Schools On Ghostwriting More
Medical Schools Quizzed on Ghostwriting More
Question for NIH: Does Money Taint Medicine? More
Patents and Generics
FTC Eyes Supply Dispute Between Drugmakers More
Generics Firms Call Big Pharma Anticompetitive More
Generic and Brand-Name Drug Makers Face Off More
GPhA: Senate Health Bill Lifts Brand Profits to New Heights At Consumer Expense More
Monopoly on Expensive, Lifesaving Drugs Unfair More
EU Wants Details On Brand Name & Generic Deals More
Advertising and Marketing
How Industry Spends $1 Billion a Year on Continuing Medical Education More
House Bill Wants Pharma To Disclose CME Funding More
Health-Bill Disclosure Rule Is Resisted More
Did State Medicaid Programs Finance Plavix DTC Advertising? More
Judge: Send Federal Seroquel Suits to Courts More
Biotech Can Sue Consultant Over Whistleblower Loss More
A Feast of Food for Thought on Social Media  More
Google's Pitch to FDA for Online Drug Ads More
Drug Makers to Press for Guidance on Web Marketing More
Pharma Watch
Biogen Shareholder Denounces CEO Pay More
Moody's on Pharma: Outlook Is Negative, But it Could Be Worse More
Pharma Credit Ratings to Suffer Through 2012 More
Should Pharma 'Blow Up' Its Sales Model? More
Pfizer's Generics Business Takes Shape More
Which Drug Companies Could Be Private-Equity Targets? More
For Lilly's R&D Chief, a $2 Million Exit Handshake More
Novartis Gives Thumbs Down To R&D In India More
PBM Watch
Groups Target CVS Caremark, Seek Privacy Violation Probe More
Coventry Health Sued CVS Caremark Over Claims More
CVS Buys Stake in Gene-Test Benefit Firm More
Express Scripts, SeaRainbow to Pioneer PBM Business in China More
Medicare and Medicaid
Part D Plan Availability in 2010 and Key Changes Since 2006 More
Seniors Struggle With Costs While Congress Debates 'Donut Hole" More
Price Negotiation for Medicare Part D: Time to Lower Costs for Seniors More
CMS Moves Up Avastin Pricing Changes More
White House Reports Billions Lost In Improper Payments For Medicare, Other Government Programs More
Medicare Part D: A Health Care Success Story More
Safety and Clinical Trials
Glaxo Warns on Batch of Swine-Flu Vaccine More
Analysis Finds Vioxx's Heart Attack Risk in 2001 More
Court Dismisses Texas Vioxx Suit Against Merck More
The Arbiter Study Is Another Setback For Merck More
U.S., Europe Review Safety of Abbott Obesity Medicine More
Ranbaxy Recalls Sotret in the US More
AstraZeneca Judge to Urge Return of Seroquel Cases to Courts More
Genzyme Drops Kidney-Drug Plans Amid Pileup of Bad News More
FDA: Popular Meds Stifle Plavix Efficacy More
Why Vytorin? HHS Spends Millions On The Drug More
Consumers Union Safe Patient Project Live Forum Webcast, November 17, 2009 10am-3:30pm EST More
DC HIV Study: Can Intense Treatment Prevent Spread? More
Data From Studies of Pfizer Neurontin Drug May Have Been Skewed More
Electronic Records
Electronic Health Records Not Yet Making Impact, Patients Turn To Web More
Digital Divide Appears Between Hospitals That Treat The Rich And Poor  More
A Doc Warns of 'Magical Thinking' on Health IT More